The Viennalab HLA-B5701 RealFast™ Assay is a reliable and efficient way to prevent hypersensitivity reactions to abacavir in HIV-infected patients.
Abacavir is commonly used in combination therapy for the treatment of HIV, but the HLA-B57:01 allele is strongly associated with abacavir hypersensitivity, and HLA-B57:01 positive patients must be excluded from such treatment. Screening patients for the presence of HLA-B57:01 before starting abacavir therapy can significantly reduce the incidence of hypersensitivity reactions. The Viennalab assay accurately determines the presence or absence of HLA-B57:01 alleles, providing a crucial tool for preventing adverse reactions.
Looking for a reliable and efficient way to prevent hypersensitivity reactions to abacavir in your HIV-infected patients? Look no further than the Viennalab HLA-B5701 RealFast™ Assay! Our assay accurately determines the presence or absence of HLA-B*57:01 alleles, providing a crucial tool for preventing adverse reactions.
Abacavir is a commonly used antiretroviral drug in combination therapy for the treatment of HIV-infected patients. However, the HLA-B57:01 allele, a variant of the human leukocyte antigen B (HLA-B) gene, is strongly associated with abacavir hypersensitivity. HLA-B57:01 positive patients must be excluded from such treatment. Screening patients for the presence of HLA-B*57:01 before starting abacavir therapy can significantly reduce the incidence of hypersensitivity reactions (HSR).
Trust in the Viennalab HLA-B5701 RealFast™ Assay to provide you with accurate and reliable results, enabling you to make informed treatment decisions for your patients. Order now and experience the convenience and efficiency of RealFast™ technology!
The kit also includes instructions for use, as well as a protocol for the detection of the HLA-B*5701 allele using real-time PCR.
Goffin Molecular Technologies is a leading Dutch company with a rich history, offering a diverse range of high-quality molecular diagnostics products from various manufacturers.
